[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Persimmon Tree Investments [@PersimmonTI](/creator/twitter/PersimmonTI) on x 9537 followers Created: 2025-07-05 18:18:17 UTC $SMMT — $AZN ? $xbi, The PD1xVEGF state of play… Bloomberg story re: ongoing discussion between $AZN and $SMMT for partnership would make a lot of sense for both parties. Had previously guessed a major rights partnering for Duggan’s $SMMT could be in the cards, though I hadn’t mentioned $AZN. Though questions remain re: ivonescimab survival advantage over pembro, pharma is beyond the merely hedging their bets stage now. The stakes are too high if PD1xVEGF is the real deal. $MRK Dean Li was instructive at Goldman Sachs last month, sharing the Merck’s strategy was to advance pembro and their PD1xVEGF (LaNova) combos aggressively and in parallel. Currently, $MRK still pairing their ADCs with Keytruda, but they have many more in the pipeline, and they stand ready to pivot those combos to PD1xVEGF without delay. The question is — as with PD1 mAbs, will it be a two person game? Because if so, the hands could be in the process of being dealt, and the tables could be turned on the erstwhile I/O powerhouse, $MRK. $BMY has made their big bet on $BNTX. And if $AZN can close the deal with $SMMT, they could be in pole position with the most advanced molecule. $MRK seems to have made its bed with LaNova, and $PFE with 3SBio, each needing to catch up in clinic. Meanwhile, $RHHBY seems set to move on from its Genentech I/O, and $NVS, perhaps no interest? But if a pharma still wants to throw their hat in the ring, there are many molecules left. However, only a couple with IP that’s stateside: $CMPX, $CBIO.  XXXXX engagements  **Related Topics** [manat](/topic/manat) [$rhhby](/topic/$rhhby) [$nvs](/topic/$nvs) [bounty](/topic/bounty) [$xbi](/topic/$xbi) [$psnl](/topic/$psnl) [$smmt](/topic/$smmt) [$azn](/topic/$azn) [Post Link](https://x.com/PersimmonTI/status/1941562290974700019)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Persimmon Tree Investments @PersimmonTI on x 9537 followers
Created: 2025-07-05 18:18:17 UTC
$SMMT — $AZN ?
$xbi, The PD1xVEGF state of play…
Bloomberg story re: ongoing discussion between $AZN and $SMMT for partnership would make a lot of sense for both parties.
Had previously guessed a major rights partnering for Duggan’s $SMMT could be in the cards, though I hadn’t mentioned $AZN.
Though questions remain re: ivonescimab survival advantage over pembro, pharma is beyond the merely hedging their bets stage now. The stakes are too high if PD1xVEGF is the real deal.
$MRK Dean Li was instructive at Goldman Sachs last month, sharing the Merck’s strategy was to advance pembro and their PD1xVEGF (LaNova) combos aggressively and in parallel. Currently, $MRK still pairing their ADCs with Keytruda, but they have many more in the pipeline, and they stand ready to pivot those combos to PD1xVEGF without delay.
The question is — as with PD1 mAbs, will it be a two person game? Because if so, the hands could be in the process of being dealt, and the tables could be turned on the erstwhile I/O powerhouse, $MRK.
$BMY has made their big bet on $BNTX.
And if $AZN can close the deal with $SMMT, they could be in pole position with the most advanced molecule.
$MRK seems to have made its bed with LaNova, and $PFE with 3SBio, each needing to catch up in clinic.
Meanwhile, $RHHBY seems set to move on from its Genentech I/O, and $NVS, perhaps no interest?
But if a pharma still wants to throw their hat in the ring, there are many molecules left. However, only a couple with IP that’s stateside: $CMPX, $CBIO.
XXXXX engagements
Related Topics manat $rhhby $nvs bounty $xbi $psnl $smmt $azn